Dupixent (dupilumab) - Sanofi, Regeneron
AD-Sys: Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation (clinicaltrials.gov) - Oct 23, 2026 - P=N/A | N=25 | Completed | Sponsor: Charite University, Berlin, Germany | Recruiting ➔ Completed 
Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immune Modulation • Immunology
http://clinicaltrials.gov/ct2/show/NCT05098821
 
Oct 23, 2026
 
Prev Next